Skip to main
EPRX
EPRX logo

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals Inc. benefits from the recent CLDX announcement, which eliminates a potential competitor in the treatment of eosinophilic esophagitis (EoE) and underscores the effectiveness of its EP-104 therapeutic approach. The encouraging results from the Phase 1b/2a portion of the RESOLVE study indicate sustained drug release and improved treatment outcomes, particularly with the 48 mg dosage demonstrating active drug release nine months post-administration. Additionally, management's anticipation of a positive Phase 2b trial outcome could pave the way for a pivotal Phase 3 trial in early 2027, highlighting a strategic path toward potential regulatory approval.

Bears say

Eupraxia Pharmaceuticals faces a negative outlook primarily due to potential risks associated with cross-border supply issues and tariffs that could impact its operations and profitability. The reliance on its proprietary Diffusphere technology raises concerns about the scalability and cost-effectiveness of its drug delivery solutions in a competitive biotechnology landscape. Additionally, unmet medical needs, while presenting opportunities, may also reflect significant market challenges that could hinder the successful adoption and revenue generation of its products.

EPRX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Strong Buy based on their latest research and market trends.

According to 3 analysts, EPRX has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.